Last reviewed · How we verify
placebo to match albiglutide
This drug is a placebo that matches the mechanism of albiglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist.
This drug is a placebo that matches the mechanism of albiglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. Used for Type 2 diabetes.
At a glance
| Generic name | placebo to match albiglutide |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
As a placebo, it does not have a direct mechanism of action. However, it is designed to mimic the effects of albiglutide, which works by binding to and activating the GLP-1 receptor, thereby increasing insulin secretion and decreasing glucagon levels.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects (PHASE4)
- Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus (PHASE2)
- Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus (PHASE3)
- Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus (PHASE4)
- A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus (PHASE3)
- Albiglutide Thorough ECG Study in Healthy Volunteers (PHASE1)
- A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment. (PHASE3)
- Dose Ranging Study of Albiglutide in Japanese Subjects (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo to match albiglutide CI brief — competitive landscape report
- placebo to match albiglutide updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI